Sanofi (SNY)
(Delayed Data from NSDQ)
$53.10 USD
+1.90 (3.71%)
Updated Jul 25, 2024 04:00 PM ET
After-Market: $53.09 -0.01 (-0.02%) 5:10 PM ET
3-Hold of 5 3
B Value D Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$53.10 USD
+1.90 (3.71%)
Updated Jul 25, 2024 04:00 PM ET
After-Market: $53.09 -0.01 (-0.02%) 5:10 PM ET
3-Hold of 5 3
B Value D Growth C Momentum C VGM
Zacks News
The Zacks Analyst Blog Highlights: Pepsico, Disney, Sanofi, Diageo and HCA
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pepsico, Disney, Sanofi, Diageo and HCA
Top Ranked Income Stocks to Buy for February 6th
by Zacks Equity Research
Here are three stocks with buy rank and strong income characteristics for investors to consider today, February 6th:
Can Sanofi (SNY) Keep the Earnings Surprise Streak Alive?
by Zacks Equity Research
Sanofi (SNY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Sanofi's Myeloma Candidate Meets Goal in Phase III Study
by Zacks Equity Research
Sanofi's (SNY) late-stage candidate, isatuximab, achieves the primary endpoint in a pivotal study by prolonging progression free survival in patients with relapsed/refractory multiple myeloma.
Top Research Reports for Pepsico, Walt Disney & Sanofi
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Pepsico (PEP), Walt Disney Company (DIS) and Sanofi (SNY).
Regeneron (REGN) to Report Q4 Earnings: Is a Beat in Store?
by Zacks Equity Research
Strong Eylea and Dupixent sales are likely to propel better-than-expected results for Regeneron (REGN) when it reports fourth-quarter results.
Merck's Pneumococcal Vaccine Gets Breakthrough Therapy Status
by Zacks Equity Research
Merck's (MRK) investigational pneumococcal vaccine V114 gets FDA's Breakthrough Therapy designation for prevention of invasive pneumococcal disease.
Pharma Stock Roundup: JNJ & BMY's Q4 Earnings, Study Failures at LLY & ABBV
by Zacks Equity Research
J&J (JNJ) and Bristol-Myers (BMY) kick off earnings for pharma sector. Lilly (LLY) and AbbVie (ABBV) announce failure of late-stage studies.
Top Ranked Income Stocks to Buy for January 25th
by Zacks Equity Research
Here are three stocks with buy rank and strong income characteristics for investors to consider today, January 25th:
Sanofi's (SNY) Influenza Vaccine Gets FDA Approval for Kids
by Zacks Equity Research
Sanofi's (SNY) influenza vaccine, Fluzone Quadrivalent (0.5mL dose), gains an FDA nod for treating children in six to 35-month age group.
Top Ranked Income Stocks to Buy for January 23rd
by Zacks Equity Research
Here are four stocks with buy rank and strong income characteristics for investors to consider today, January 23rd:
Alnylam & Medison Partner to Market RNAi Products in Israel
by Zacks Equity Research
Alnylam (ALNY) partners with Israel's Medison Pharma to commercialize Onpattro and other RNAi pipeline candidates under development in the former's portfolio.
Merck's Partner Gets FDA Nod for Herceptin Biosimilar
by Zacks Equity Research
Merck's (MRK) partner, Samsung Bioepis Co. gets FDA approval for Ontruzant, a Herceptin Biosimilar.
Top Ranked Income Stocks to Buy for January 21st
by Zacks Equity Research
Here are four stocks with buy rank and strong income characteristics for investors to consider today, January 21st:
Pharma Stock Roundup: Regulatory Updates in Focus at PFE, BMY, RHHBY, SNY
by Zacks Equity Research
Pfizer's (PFE) tafamidis application gets FDA's priority review. Regulatory updates for Roche's (RHHBY) and Bristol-Myers'(BMY) cancer combination drugs in focus.
Top Ranked Income Stocks to Buy for January 18th
by Zacks Equity Research
Here are four stocks with buy rank and strong income characteristics for investors to consider today, January 18th
Regeneron (REGN) Sails Steady on Label Expansion of Drugs
by Zacks Equity Research
Regeneron's (REGN) performance has been steady in the past six months even as the overall industry declines.
Emergent (EBS) Up on '19 View, Posts Preliminary '18 Results
by Zacks Equity Research
Emergent (EBS) provides preliminary results for 2018 and guidance for 2019. The results exceed estimates.
Regeneron, Sanofi Restructure Immuno-Oncology Collaboration
by Zacks Equity Research
Regeneron (REGN) amends its existing agreement with Sanofi and selects two clinical-stage bispecific antibodies for the ongoing collaboration.
Emergent (EBS) Files Application for Emergency Use of NuThrax
by Zacks Equity Research
Emergent (EBS) submits an application to the FDA for the emergency use of its anthrax vaccine candidate, NuThrax.
Sanofi Wins FDA Nod for Pediatric Hexavalent Combo Vaccine
by Zacks Equity Research
Sanofi (SNY) gains an FDA approval for its pediatric hexavalent combination vaccine, Vaxelis.
The Zacks Analyst Blog Highlights: Apple, Microsoft, Mastercard, Sanofi and Dominion Energy
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Apple, Microsoft, Mastercard, Sanofi and Dominion Energy
Top Analyst Reports: Apple, Microsoft, Mastercard & More
by Kalyan Nandy
Today's Research Daily features updated research reports on 16 major stocks including Apple Inc. (AAPL), Microsoft Corporation (MSFT) and Mastercard Inc. (MA).
Mylan (MYL) Gets Favorable Ruling Against Sanofi's Lantus
by Zacks Equity Research
Mylan (MYL) gets a favorable ruling from the U.S. PTAB against Sanofi for Lantus.
5 Top Drug/Biotech Merger & Acquisition Targets for 2019
by Kinjel Shah
Here are five stocks that are attractive and most likely to be takeout targets in 2019.